Glenmark Pharmaceuticals Limited US, Thursday announced the launch of Epinephrine Injection USP, 10 mg/10 mL Multiple-Dose Vial.
The company added that the newly launched product is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 10 mg/10 mL, of BPI Labs, LLC.
According to IQVIA sales data for the 12-month period ending December 2024, the Epinephrine Injection USP, 10 mg/10 mL market achieved annual sales of approximately $42.7 million, the company stated.
For comments and feedback: editorial@rttnews.com